| PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension. | |
| | |
MedLine Citation:
|
PMID: 19666838 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists have been shown to protect the cerebral vasculature, including the blood-brain barrier. In the present study, we investigated the effect of the PPAR-gamma agonist rosiglitazone on changes in venous permeability during chronic hypertension induced by nitric oxide synthase inhibition. Female Sprague-Dawley rats were either treated with N(G)-nitro-L-arginine methyl ester (L-NAME; 0.5 g/l in drinking water) for 5 wk (HTN; n = 8), L-NAME for 5 wk plus the PPAR-gamma agonist rosiglitazone (20 mg/kg in food) for the last 3 wk (HTN + Rosi; n = 5), L-NAME for 5 wk plus the superoxide dismutase mimetic Tempol (1 mmol/l in drinking water) for the last 3 wk (HTN + Tempol; n = 8), or were untreated controls (n = 9). Fluid filtration (J(v)/S) and hydraulic conductivity (L(p)) of cerebral veins were compared in vitro between groups after a step increase in pressure from 10 to 25 mmHg to mimic the change in hydrostatic pressure during acute hypertension. Hypertension increased J(v)/S by 2.2-fold and L(p) by 3.2-fold. Rosiglitazone treatment after 2 wk of hypertension completely reversed the increased J(v)/S and L(p) that occurred during hypertension, whereas Tempol had no effect. These results demonstrate that rosiglitazone was effective at reversing changes in venous permeability that occurred during chronic hypertension, an effect that does not appear to be related to its antioxidant properties. Our findings suggest that PPAR-gamma may be a key regulator of blood-brain barrier permeability and a potential therapeutic target during hypertension. |
| | |
Authors:
|
Tim J M Roberts; Abbie C Chapman; Marilyn J Cipolla |
Related Documents
:
|
1280688 - Nitric oxide synthase is critical in mediating basal forebrain regulation of cortical c... 16644708 - Aldose reductase pathway inhibition improved vascular and c-fiber functions, allowing f... 9072328 - Blood pressure-related changes of endothelium-dependent relaxation in the aorta from sh... 12923398 - Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-depen... 12900178 - The critical closing pressure of the cerebral circulation. 21137998 - Photoluminescence and raman studies of y2o3:eu(3+) nanotubes under high pressure. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2009-08-07 |
Journal Detail:
|
Title: American journal of physiology. Heart and circulatory physiology Volume: 297 ISSN: 1522-1539 ISO Abbreviation: Am. J. Physiol. Heart Circ. Physiol. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-09-25 Completed Date: 2009-10-08 Revised Date: 2011-11-24 |
Medline Journal Info:
|
Nlm Unique ID: 100901228 Medline TA: Am J Physiol Heart Circ Physiol Country: United States |
Other Details:
|
Languages: eng Pagination: H1347-53 Citation Subset: IM |
Affiliation:
|
1Departments of Neurology, Obstetrics, Gynecology and Reproductive Sciences, and Pharmacology, University of Vermont, Burlington, Vermont 05405, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / pharmacology* Antioxidants / pharmacology Blood Pressure / drug effects Brain Edema / etiology, physiopathology, prevention & control Capillary Permeability / drug effects* Cerebral Veins / drug effects*, metabolism, physiopathology Cerebrovascular Circulation / drug effects* Chronic Disease Cyclic N-Oxides / pharmacology Disease Models, Animal Female Hydrostatic Pressure Hypertension / chemically induced, drug therapy*, metabolism, physiopathology NG-Nitroarginine Methyl Ester PPAR gamma / agonists* Rats Rats, Sprague-Dawley Spin Labels Thiazolidinediones / pharmacology* Time Factors |
| Grant Support | |
ID/Acronym/Agency:
|
NS043316/NS/NINDS NIH HHS; NS045940/NS/NINDS NIH HHS; R01 NS043316-01A2/NS/NINDS NIH HHS; R01 NS045940-05A2/NS/NINDS NIH HHS; R01 NS045940-08/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Antioxidants; 0/Cyclic N-Oxides; 0/PPAR gamma; 0/Spin Labels; 0/Thiazolidinediones; 122320-73-4/rosiglitazone; 2226-96-2/tempol; 50903-99-6/NG-Nitroarginine Methyl Ester |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Left ventricular remodeling with exercise in hypertension.
Next Document: Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves.